c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer

被引:118
作者
Stal, O
Sullivan, S
Wingren, S
Skoog, L
Rutqvist, LE
Carstensen, JM
Nordenskjold, B
机构
[1] KAROLINSKA HOSP,DIV CYTOL,S-10401 STOCKHOLM,SWEDEN
[2] KAROLINSKA HOSP,CTR ONCOL,S-10401 STOCKHOLM,SWEDEN
[3] LINKOPING UNIV,DEPT HLTH & SAFETY,S-581 LINKOPING,SWEDEN
关键词
adjuvant treatment; breast cancer; c-erbB-2; chemotherapy; CMF; drug resistance; local recurrence; radiotherapy; S-phase fraction;
D O I
10.1016/0959-8049(95)00344-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Frozen tissue from primary tumours of 152 premenopausal breast cancer patients, who participated in a trial comparing radiotherapy with adjuvant chemotherapy (cyclophosphamide, methotrexate, 5-fluorouracil, CMF), was analysed for c-erbB-2 protein expression, measured by flow cytometry. The relative risk of distant recurrence or death in the chemotherapy group as compared with the radiotherapy group was 3.0 (95% confidence interval (CI) 1.1-7.8) for patients whose tumours showed high c-erbB-2 levels and 0.87 (95% CI 0.43-1.7) for those with tumours with low levels of c-erbB-2 protein. Patients with highly proliferative tumours that did not overexpress c-erbB-2 benefited most, in terms of survival, from CMF. In addition, we found an increased risk of locoregional recurrence for tumours overexpressing c-erbB-2 when radiotherapy was replaced by chemotherapy.
引用
收藏
页码:2185 / 2190
页数:6
相关论文
共 31 条
[1]   HER-2/NEU IN NODE-NEGATIVE BREAST-CANCER - PROGNOSTIC-SIGNIFICANCE OF OVEREXPRESSION INFLUENCED BY THE PRESENCE OF INSITU CARCINOMA [J].
ALLRED, DC ;
CLARK, GM ;
TANDON, AK ;
MOLINA, R ;
TORMEY, DC ;
OSBORNE, CK ;
GILCHRIST, KW ;
MANSOUR, EG ;
ABELOFF, M ;
EUDEY, L ;
MCGUIRE, WL .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :599-605
[2]  
ARTEAGA CL, 1993, P AM SOC CLIN ONCOL, V12, P101
[3]   POST-MASTECTOMY MEGAVOLTAGE RADIOTHERAPY - THE OSLO AND STOCKHOLM TRIALS [J].
AUQUIER, A ;
RUTQVIST, LE ;
HOST, H ;
ROTSTEIN, S ;
ARRIAGADA, R .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :433-437
[4]   RELATIONSHIP BETWEEN C-ERBB-2 IMMUNOREACTIVITY AND THYMIDINE LABELING INDEX IN BREAST-CARCINOMA INSITU [J].
BARNES, DM ;
MEYER, JS ;
GONZALEZ, JG ;
GULLICK, WJ ;
MILLIS, RR .
BREAST CANCER RESEARCH AND TREATMENT, 1991, 18 (01) :11-17
[5]   OVEREXPRESSION OF THE C-ERBB-2 ONCOPROTEIN - WHY DOES THIS OCCUR MORE FREQUENTLY IN DUCTAL CARCINOMA INSITU THAN IN INVASIVE MAMMARY-CARCINOMA AND IS THIS OF PROGNOSTIC-SIGNIFICANCE [J].
BARNES, DM ;
BARTKOVA, J ;
CAMPLEJOHN, RS ;
GULLICK, WJ ;
SMITH, PJ ;
MILLIS, RR .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :644-648
[6]   ESTROGEN-DEPENDENT, TAMOXIFEN-RESISTANT TUMORIGENIC GROWTH OF MCF-7 CELLS TRANSFECTED WITH HER2/NEU [J].
BENZ, CC ;
SCOTT, GK ;
SARUP, JC ;
JOHNSON, RM ;
TRIPATHY, D ;
CORONADO, E ;
SHEPARD, HM ;
OSBORNE, CK .
BREAST CANCER RESEARCH AND TREATMENT, 1992, 24 (02) :85-95
[7]   ERBB2 AMPLIFICATION IS ASSOCIATED WITH TAMOXIFEN RESISTANCE IN STEROID-RECEPTOR POSITIVE BREAST-CANCER [J].
BORG, A ;
BALDETORP, B ;
FERNO, M ;
KILLANDER, D ;
OLSSON, H ;
RYDEN, S ;
SIGURDSSON, H .
CANCER LETTERS, 1994, 81 (02) :137-144
[8]   EARLY BREAST-CANCER - PREDICTORS OF BREAST RECURRENCE FOR PATIENTS TREATED WITH CONSERVATIVE SURGERY AND RADIATION-THERAPY [J].
BOYAGES, J ;
RECHT, A ;
CONNOLLY, JL ;
SCHNITT, SJ ;
GELMAN, R ;
KOOY, H ;
LOVE, S ;
OSTEEN, RT ;
CADY, B ;
SILVER, B ;
HARRIS, JR .
RADIOTHERAPY AND ONCOLOGY, 1990, 19 (01) :29-41
[9]  
COX DR, 1972, J R STAT SOC B, V34, P187
[10]   LONG-TERM SURVIVAL IN BREAST-CANCER RELATED TO OVEREXPRESSION OF THE C-ERBB-2 ONCOPROTEIN - AN IMMUNOHISTOCHEMICAL STUDY USING MONOCLONAL-ANTIBODY NCL-CB11 [J].
DYKINS, R ;
CORBETT, IP ;
HENRY, JA ;
WRIGHT, C ;
YUAN, J ;
HENNESSY, C ;
LENNARD, TJW ;
ANGUS, B ;
HORNE, CHW .
JOURNAL OF PATHOLOGY, 1991, 163 (02) :105-110